Request for Pre-proposals

Translational and Preclinical Science


The Osteosarcoma Institute (OSI) was established in November 2017 to develop a comprehensive, rational strategy that will lead to a major improvement in the life expectancy of osteosarcoma patients, particularly those with relapsed and metastatic disease. To this end, OSI has announced a separate, complementary RFP (Request for Proposals) to support a clinical study to test the activity of a novel therapeutic approach for osteosarcoma patients. As part of a comprehensive approach to improve outcomes for osteosarcoma patients and aligned with this initial support of a clinical study, OSI also hereby seeks to support translational and preclinical research proposals in the area of osteosarcoma metastasis.

 Summer 2018 Request (note: closed, award pending)

Translational and preclinical research pre-proposals in the area of osteosarcoma metastasis

Specifically, this translational and preclinical science RFP seeks to support the development of a novel therapeutic approach that targets pulmonary metastatic osteosarcoma lesions or the process of pulmonary metastatic progression. The features of an optimal preclinical dataset for osteosarcoma metastasis drug development have been reported (Khanna et al, Clin Can Res 2014). Briefly, an ideal dataset would have the following features:

  • a drug target demonstrated to be relevant in osteosarcoma metastasis, rigorously and mechanistically tested in multiple preclinical models across preclinical model species, and in human osteosarcoma metastatic cells and/or lesions;
  • the availability of a therapeutic candidate or drug suitable for preclinical studies; a testable PD marker of effective drug exposure;
  • a correlative biomarker that may be translated to human patients in support of optimal dosing.

Applicants are encouraged to describe how their proposal will contribute to the establishment of such a dataset, either by addressing existing gaps or otherwise.

Funding will include up to $250,000 per year, not to exceed a total of $500,000. Funding can be used to support any aspect of the preclinical and translational path, with indirect costs not to exceed 10%. 

Published by the Osteosarcoma Institute on August 1, 2018. Updated April 2019.